PCSK9 inhibitors × lipids

SynthesisJAMA2016

Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.

Luca A Lotta et al.PubMed ↗Full text ↗Publisher ↗

  • PCSK9 genetic variantslooks good hereLower type 2 diabetes.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

PCSK9 genetic variants went with lower type 2 diabetes

−1.19−1.38 to −1.02

PCSK9 genetic variants vs non-carriers, in PCSK9

As reported

difference −1.19, 95% CI −1.38 to −1.02

Who was studied, and how

801people with dyslipidemia, in this paper

Already taking PCSK9 genetic variants, or nottheir own situation, not assigned

on PCSK9 genetic variants
not on carriers

PCSK9 genetic variants went with lower type 2 diabetes−1.19

correlation, not a test

the abstract, start to end

predicted reduction in LDL-C was 1.19 (95% CI, 1.02-1.38; P = .03).

← favours treatmentfavours comparator →
could be chance
Type 2 diabetesPCSK9 genetic variants vs non-carriers, in PCSK9
−1.19−1.38 to −1.02
PCSK9 inhibitorsLipids
1 / 4

189 papers cite itlatest 60 shown

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 27701660